Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

Michel L Peters; Claudine de Meijer; Dirk Wyndaele; Walter Noordzij; Annemarie M Leliveld-Kors; Joan van den Bosch; Pieter H van den Berg; Agni Baka; Jennifer G Gaultney

doi:10.1007/s40258-017-0364-4

Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

Appl Health Econ Health Policy. 2018 Feb;16(1):145. doi: 10.1007/s40258-017-0364-4.

Authors

Michel L Peters¹, Claudine de Meijer², Dirk Wyndaele³, Walter Noordzij⁴, Annemarie M Leliveld-Kors⁵, Joan van den Bosch⁶, Pieter H van den Berg⁷, Agni Baka¹, Jennifer G Gaultney⁸

Affiliations

¹ Real World Strategy and Analytics, Mapi Group, Houten, The Netherlands.
² Bayer B.V., Mijdrecht, The Netherlands.
³ Department of Nuclear Medicine, Catharina Ziekenhuis, Eindhoven, The Netherlands.
⁴ Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
⁵ Department of Urology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.
⁶ Department of Internal Medicine, Albert Schweitzer Ziekenhuis, Dordrecht, The Netherlands.
⁷ Department of Internal Medicine, Tergooi Ziekenhuizen, Hilversum, The Netherlands.
⁸ Real World Strategy and Analytics, Mapi Group, The Translation and Innovation Hub Building, 5th Floor, 80 Wood Lane, White City, London, W12 OBZ, UK. jgaultney@mapigroup.com.

Abstract

The article Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer, written by Michel L. Peters, Claudine de Meijer, Dirk Wyndaele, Walter Noordzij, Annemarie M. Leliveld-Kors, Joan van den Bosch, Pieter H. van den Berg, Agni Baka, Jennifer G. Gaultney was originally published electronically on the publisher's internet portal (currently SpringerLink) on 2nd September, 2017 without open access.

Publication types

Published Erratum